OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation
In women with metastatic HER2-negative breast cancer and an inherited BRCA mutation, the PARP inhibitor tablet olaparib delayed progression by almost three months compared with chemotherapy and caused fewer severe side effects.
Overview
Phase 3 trial of 302 patients with HER2-negative metastatic breast cancer and a germline BRCA1 or BRCA2 mutation, previously treated with up to two chemotherapy lines, randomised 2:1 to olaparib or single-agent chemotherapy of physician's choice.
Median progression-free survival was 7.0 versus 4.2 months (hazard ratio 0.58) with a response rate of 59.9 versus 28.8 percent; overall survival was not significantly different, though a benefit appeared in patients who had not received chemotherapy for metastatic disease.
- Median progression-free survival 7.0 vs 4.2 months; hazard ratio 0.58.
- Objective response 59.9 percent vs 28.8 percent; grade 3 or worse adverse events 36.6 percent vs 50.5 percent.
Germline BRCA testing became part of metastatic breast cancer work-up, and olaparib (with talazoparib after EMBRACA) is a standard option, especially for triple-negative disease.
- No overall survival benefit in the whole population.
- Platinum chemotherapy was not in the comparator arm.
Similar pages
not linked directly; found by shared links- Key paperKEYNOTE-355: pembrolizumab plus chemotherapy for PD-L1-positive advanced triple-negative breast cancer
Shares Metastatic triple-negative breast cancer, New England Journal of Medicine.
- Key paperPROfound: olaparib for metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations
Shares Olaparib, New England Journal of Medicine.
- TrialTo Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
- TermGermline BRCA mutation (gBRCA)
Shares OlympiAD, Metastatic triple-negative breast cancer, Olaparib.
- Key paperSOLO-1: two years of olaparib maintenance after first-line chemotherapy for BRCA-mutated ovarian cancer
Shares Olaparib, New England Journal of Medicine.
- Key paperPAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours
Shares Olaparib, New England Journal of Medicine.
- TreatmentEribulin
- Key paperDESTINY-Breast04: trastuzumab deruxtecan works in HER2-low breast cancer, creating a new treatable group
Shares Metastatic triple-negative breast cancer, New England Journal of Medicine.